Spero Therapeutics (SPRO) Enterprise Value (2016 - 2025)
Spero Therapeutics (SPRO) has disclosed Enterprise Value for 10 consecutive years, with -$48.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 36.27% year-over-year to -$48.6 million, compared with a TTM value of -$48.6 million through Sep 2025, up 36.27%, and an annual FY2024 reading of -$52.9 million, up 30.71% over the prior year.
- Enterprise Value was -$48.6 million for Q3 2025 at Spero Therapeutics, down from -$31.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$27.7 million in Q2 2021 and bottomed at -$146.4 million in Q4 2021.
- Average Enterprise Value over 5 years is -$76.9 million, with a median of -$76.3 million recorded in 2023.
- The sharpest move saw Enterprise Value soared 61.24% in 2021, then crashed 215.7% in 2022.
- Year by year, Enterprise Value stood at -$146.4 million in 2021, then rose by 25.47% to -$109.1 million in 2022, then surged by 30.04% to -$76.3 million in 2023, then soared by 30.71% to -$52.9 million in 2024, then grew by 8.08% to -$48.6 million in 2025.
- Business Quant data shows Enterprise Value for SPRO at -$48.6 million in Q3 2025, -$31.2 million in Q2 2025, and -$52.9 million in Q4 2024.